Importantly, Bcl-2 and other anti-apoptotic proteins reported overexpressed in several cancers are associated with the development of resistance to anticancer agents [60, 61], highlighting the therapeutic potential of targeting Bcl-2 in cancer treatment. This evidence concerns the gene BCL2 and cancer.